Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists

Atkinson, Victoria, Long, Georgina V., Menzies, Alexander M., McArthur, Grant, Carlino, Matteo S., Millward, Michael, Roberts-Thomson, Rachel, Brady, Benjamin, Kefford, Richard, Haydon, Andrew and Cebon, Jonathan (2016) Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pacific Journal of Clinical Oncology, 12 S7: 5-12. doi:10.1111/ajco.12656


Author Atkinson, Victoria
Long, Georgina V.
Menzies, Alexander M.
McArthur, Grant
Carlino, Matteo S.
Millward, Michael
Roberts-Thomson, Rachel
Brady, Benjamin
Kefford, Richard
Haydon, Andrew
Cebon, Jonathan
Title Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists
Journal name Asia Pacific Journal of Clinical Oncology   Check publisher's open access policy
ISSN 1743-7563
1743-7555
Publication date 2016-12-01
Sub-type Article (original research)
DOI 10.1111/ajco.12656
Open Access Status Not yet assessed
Volume 12
Issue S7
Start page 5
End page 12
Total pages 8
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2017
Language eng
Abstract BRAF mutations occur commonly in metastatic melanomas and inhibition of mutant BRAF and the downstream kinase MEK results in rapid tumor regression and prolonged survival in patients. Combined therapy with BRAF and MEK inhibition improves response rate, progression free survival and overall survival compared with single agent BRAF inhibition, and reduces the skin toxicity that is seen with BRAF inhibitor monotherapy. However, this combination is associated with an increase in other toxicities, particularly drug-related pyrexia, which affects approximately 50% of patients treated with dabrafenib and trametinib (CombiDT). We provide guidance on managing adverse events likely to arise during treatment with combination BRAF and MEK inhibition with CombiDT: pyrexia, skin conditions, fatigue; and discuss management of CombiDT during surgery and radiotherapy. By improving tolerability and in particular preventing unnecessary treatment cessations or reduction in drug exposure, best outcomes can be achieved for patients undergoing CombiDT therapy.
Keyword BRAF
Dabrafenib
MEK
Melanoma
Pyrexia
Trametinib
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin Only - School of Medicine
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 05 Mar 2017, 01:00:36 EST by Web Cron on behalf of Learning and Research Services (UQ Library)